Non-steroidal anti-inflammatory drugs that cause relatively little gastric damage

Journal of Gastroenterology and Hepatology (Australia)

Volumn 13, Issue SUPPL.1, 1998, Pages

  Tavares, Ignatius A ^a   Bennett, Alan ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acemetacin; COX 1; COX 2; Human gastric mucosa; Leucocytes; Nimesulide

Indexed keywords

ACEMETACIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INDOMETACIN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

CONFERENCE PAPER; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE; PRIORITY JOURNAL; STOMACH MUCOSA;

EID: 0031739652     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1998.tb01875.x     Document Type: Article

References (17)

1. Barrier CH, Hirchowitz BI. Current controversies in rheumatology. Controversies and management of nonsteroidal anti-inflammatory drug induced side effects on upper gastrointestinal tract. Arthritis Rheum. 1989; 32: 926-9.
2. Beardson PHS, Brown SV, Mcdevitt DG. Gastrointestinal events in patients prescribed NSAIDs: A controlled study using record linkage in Tayside. Q. J. Med. 1989; 71: 497-505.
3. Armstrong CP, Blower AL. Nonsteroidal anti-inflammatory drugs and life threatening complications of peptic ulcer disease. Gut 1987; 28: 527-32.
4. Lee SH, Soyoola E, Chamugam P et al. Selective expression of mitogen-inducible cyclo-oxygenase in macrophages stimulated with lipopolysaccharide. J. Biol. Chem. 1992; 267: 25-934-8.
5. Mizumo H, Sakamoto C, Matsuda K et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112: 387-97.
6. Morham SG, Langenbach R, Loftin CD et al. Prostaglandin Synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83: 473-82.
7. Bennett P, Slatter D. COX-2 expression in labour. In: Vane J, Botting J, Botting R, eds. Improved Non-Steroid Anti-Inflammatory Drugs. COX-2 Enzyme Inhibitors. London: Kluwer Academic Press, 1996; 167-88.
8. Rabasseda X. Safety profile of Nimesulide: Ten years of clinical experience. Drugs Today 1997; 33 (Suppl. I): 1-10.
9. Laws D. Double-blind parallel group investigation in general practice of the efficacy and tolerability of acemetacin in comparison with diclofenac, in patients suffering acute low back pain. Br. J. Clin. Res. 1994; 5: 55-64.
10. Wietfeld K, Rubsamen B, Rechziegler H, Bernard I. Acemetacin and diclofenac therapy in patients with degenerative joint disease. Med. Welt. 1986; 40: 472-7.
11. Tavares LA, Bishai PM, Bennett A. Activity of nimesulide on constitutive and inducible cyclooxygenase. Arzneim. Forch./ Drug Res. 1995; 45: 1093-5.
12. Tavares IA, Bennett A. Acemetacin and indomethacin: differential inhibition of constitutive and inducible cyclo-oxygenases in human gastric mucosa and leukocytes. Int. J. Tiss. Reac. 1993; XV: 49-53.
13. Vago T, Bevilacqua M, Norbiato G. Effect of nimesulide action time dependence on selectivity towards prostaglandin G/H synthase/cyclooxygenase activity. Arzneim. Forch./ Drug Res. 1995; 45: 1096-8.
14. Jones RW, Collins AJ, Notarini LJ, Sedman E. The pharmokinetics of acemetacin in young subjects and elderly patients. Br. J. Clin. Pharmacol. 1991; 31: 543-5.
15. Tavares IA, Collins PO, Bennett A. Inhibition of prostanoid synthesis by human gastric mucosa. Aliment. Pharmacol. Ther. 1987; 1: 617-25.
16. Bennett A, Tavares IA. NSAIDs, COX-2 inhibitors and the gut. Lancet 1995; 346: 1105.
17. Bennett A, Berti F, Ferreira SH. Nimesulide: A multifactorial therapeutic approach to the inflammatory process? A 7-year clinical experience. Drugs 1993; 46 (Suppl. 1): 1-283.